|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | HIV resistance to antiretrovlral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice显示文摘 | Blaise P Clevenbergh P Vaira D | 2002 | Acta Clin Belg2002，57，： | 1 |
| 2 | Drug-resistance genotyping in HIV-1 therapy:the VIRADAPT randomised controlled trial显示文摘 | Durant J Clevenbergh P Halfon P | 1999 | Lancet1999，353，： | 1 |
| 3 | Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study 显示文摘 | DURANT J CLEVENBERGH P GARRAFFO R | 2000 | AIDS2000，14，10： | 1 |
| 4 | HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice显示文摘 | Blaise P Clevenbergh P Vaira D | 2002 | Acta Clin Belg2002，57，4： | 1 |
| 5 | Drug resistance genotyging in HIV-1 therapy: the VIRADAPT randomised controlled trial 显示文摘 | Durant J Clevenbergh P Halfon P | 1999 | Lancet1999，353，： | 1 |
| 6 | Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing on HAA T: the VIRADAPT study, week 48 follow up显示文摘 | Clevenbergh P Durant J Halfon P | 2000 | Antivir Ther2000，5，1： | 1 |
| 7 | Drug-resistance genotyping in HIV-1 therapy:the VIRADAPT randomized controlled trial显示文摘 | Durant J Clevenbergh P Halfon P | | 0，，： | 1 |
| 8 | Persisting long-termbenefit of antiretroviral genotypic guided treatment for HIV-infected patients failing on HAART:the VIRADAPT study,week 48 follow up显示文摘 | Clevenbergh P Durant J Halfon P | | 0，，： | 1 |
| 9 | Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia显示文摘 | Byl B Clevenbergh P Jacobs F | 1999 | Clin Infect Dis1999，29，： | 1 |
| 10 | Ceftazidime - and imipenem - induced endotoxin release during treatment of gram -negative infections显示文摘 | BYL B CLEVENBERGH P KENTOS A | 2001 | Eur J Clin Microbiol Infect Dis2001，20，11： | 1 |
| 11 | Ceftazidime- and imipen- em-induced endotoxin release during treatment of gram-negative infections 显示文摘 | B Byl P Clevenbergh A Kentos | 2001 | J Clin Microbiol Infect Dis2001，20，： | 1 |
| 12 | Impact of infectious disease specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia显示文摘 | Byl B Clevenbergh P Jacobs F | 1999 | Clin Infect Dis1999，29，1： | 1 |
| 13 | HIV resistance to antiretroviral drugs;mechanisms,genotypic and phenotypic resistance testing in clinical practice显示文摘 | Blaise P Clevenbergh P Vaira D | 2002 | Acta Clin Belg2002，57，4： | 1 |
| 14 | Drug-resistance geno typing in HIV-1 therapy:the VIRADAPT randomised controlled trial显示文摘 | Durant J Clevenbergh P Halfon P | 1999 | Lancet1999，353，9171： | 1 |
| 15 | HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice显示文摘 | BLAISE P CLEVENBERGH P VAIRA D | 2002 | Acta clin belg2002，57，4： | 1 |
| 16 | HIV resistance to antiretroviral drugs:mechanisms,genotypic and phenotypic resistance testing in clinical practice显示文摘 | Blaise P Clevenbergh P Vaira D | 2002 | Acta Clin Belg2002，57，4： | 1 |
| 17 | 低收入高结核病负担国家的成人HIV/AIDS,特别是合并结核病者的处置显示文摘由于在低收入国家获得HIV抗逆转录病毒(antiretroviralARV)制剂可能性的提高,目前,许多临床医生需要ARV应用方面的培训。现在临床医生在治疗结核病(TB)时,还要进一步考虑到HIV/AIDS的情况。本文概要介绍医生处置HIV感染者时需要解决的关键问题,尤其是HIV/TB双重感染者。初级卫生保健医生要对所有提示HIV感染的症状、体征者和所有结核病患者进行HIV快速检测诊断。本文主要内容为:对HIV检测前和检测后的咨询问题进行探讨。对HIV感染者进行评估,确定临床分期;通过某些实验室检查判断免疫抑制的程度,以便确定应用ARV治疗和结核病预防性治疗的最佳时机。ARV治疗需要良好的依从性,建议劝导和加强依从性。介绍ARV治疗方案和患者随访要求。优先治疗结核病。不管是否合并HIV感染,治疗结核病的原则是相同的。对合并结核病的患者应用ARV提出了建议。必须建立标准化和不断充实的信息系统,以便监控HIV与结核病双重感染者的处置及结核病和HIV联合防治的执行情况。通过对结核病患者进行HIV感染的筛查,发现HIV感染病例,并对其进行诊断和处置,医生能为减少HIV负担做出贡献,同样也为减少结核病负担做出贡献。 | P. I. Fujiwara P. Clevenbergh R. A. Dlodlo 范永德 | 2006 | 国际结核病与肺部疾病杂志2006，1，1： | 0 |
| 18 | Serratia marcescens and other non-AACEK GNB endocarditis: A case report and review of literature显示文摘BACKGROUND Non-Aggregatibacter aphrophilus,Aggregatibacter actinomycetemcomitans,Cardiobacterium hominis,Eikenella corrodens,Kingella spp.(non-AACEK)gramnegative bacilli(GNBs)are an infrequent and challenging cause of endocarditis associated previously with mainly intravenous drug use.Currently,this pathology has increasingly become a healthcare-associated issue.Current guidelines do not clearly define the management of non-AACEK GNB endocarditis due to a lack of prospective trials.We review characteristics,outcomes and treatment of non-AACEK GNB endocarditis,in particular Serratia marcescens endocarditis.CASE SUMMARY We describe the case report of a 46-year-old man who presented to the emergency department with high-grade fever and a purulent exudate on an intracardiac device site.Serratia marcescens mitral valve endocarditis as a consequence of complicated generator pocket infection was diagnosed.The patient was treated with complete device removal and a long course of broadspectrum antibiotics for 6 wk after surgery with intravenous piperacillintazobactam and ciprofloxacin,which was later switched to oral ciprofloxacin and sulfamethoxazole-trimethoprim.The patient had complete resolution of symptoms and inflammatory parameters at the end of the treatment and at follow-up.CONCLUSION Long-term dual-antibiotic therapy containing a beta-lactam is indicated for most non-AACEK GNB endocarditis, whereas valve surgery may not be necessary inall patients. | Helena Mertes Marielle Morissens Bhavna Mahadeb Evelyne Maillart Anthony Moreau Philippe Clevenbergh | 2019 | World Journal of Clinical Infectious Diseases2019，9，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员